AstraZeneca plc stock (GB0009895292): Global pharma leader with strong oncology pipeline

AstraZeneca plc, a leading biopharmaceutical company, continues to drive growth through its innovative oncology, rare diseases, and cardiovascular portfolios, offering key insights for US investors tracking global healthcare trends.

AstraZeneca plc maintains its position as a major player in the global biopharmaceutical industry, with a focus on oncology, rare diseases, and bioPharmaceuticals including cardiovascular, renal, and respiratory care. The company reported robust financial performance in its latest full-year results for 2025, published on February 27, 2026, showing total revenue of $47.6 billion, up 18% at constant exchange rates, driven by strong sales of oncology drugs like Enhertu and Imfinzi, according to AstraZeneca Annual Report as of 02/27/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca plc
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Cambridge, UK
• Core markets: US, Europe, China, Emerging Markets
• Key revenue drivers: Oncology, rare diseases, CVRM
• Home exchange/listing venue: Nasdaq (AZN), LSE
• Trading currency: USD, GBP

AstraZeneca plc: core business model

AstraZeneca plc operates as a science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily in oncology, rare diseases, and bioPharmaceuticals. The company's business model emphasizes innovation through R&D investments, strategic partnerships, and a global commercial presence. In 2025, AstraZeneca invested $11.3 billion in R&D, representing 24% of revenue, supporting a pipeline of over 180 projects, as detailed in its annual report published February 27, 2026, according to AstraZeneca Annual Report as of 02/27/2026.

This model has enabled AstraZeneca to achieve leadership in areas like antibody-drug conjugates (ADCs) and cell therapies. The company generates revenue through product sales across three main therapy areas: Oncology (53% of 2025 revenue), Rare Diseases (19%), and BioPharmaceuticals (28%). Strategic acquisitions, such as the $1.25 billion deal for Proximal Therapeutics in 2025, bolster its rare disease portfolio, per company disclosures.

Main revenue and product drivers for AstraZeneca plc

Oncology remains the primary revenue driver, with key products including Enhertu, which generated $3.8 billion in 2025 sales, up 65% year-over-year, and Imfinzi at $4.2 billion, up 20%, as reported in the full-year 2025 results on February 27, 2026, via AstraZeneca Press Release as of 02/27/2026. Tagrisso and Lynparza also contribute significantly, with combined sales exceeding $6 billion.

In Rare Diseases, products like Ultomiris and Strensiq drive growth, while BioPharmaceuticals benefits from Farxiga ($5.9 billion) and Symbicort. China represents 20% of total revenue, highlighting AstraZeneca's exposure to emerging markets. For US investors, AstraZeneca's Nasdaq listing (AZN) provides direct access, with the ADR trading at around 78 USD as of May 12, 2026, on Nasdaq, according to official exchange data.

Industry trends and competitive position

The biopharma sector is marked by rapid innovation in precision medicine and ADCs, where AstraZeneca holds a top-tier position alongside competitors like Pfizer and Merck. The global oncology market is projected to reach $400 billion by 2030, per IQVIA data published in 2025, with AstraZeneca capturing share through its datopotamab deruxtecan ADC candidate advancing in Phase III trials.

AstraZeneca's competitive edge stems from its $80 billion+ peak sales potential pipeline as of early 2026. Partnerships with Daiichi Sankyo on Enhertu exemplify its collaborative approach, positioning it well against rivals in a market emphasizing targeted therapies over traditional chemotherapy.

Why AstraZeneca plc matters for US investors

AstraZeneca plc is highly relevant for US investors due to its significant US market revenue (around 40% of total), Nasdaq listing under ticker AZN, and exposure to high-growth areas like oncology that align with US healthcare spending trends. The company's drugs like Farxiga address diabetes and heart failure, key concerns in the aging US population.

With over 50% of its pipeline focused on US FDA approvals, AstraZeneca offers diversified exposure to biopharma innovation without pure domestic risk. Its ADR structure facilitates easy trading for retail investors on US platforms.

Conclusion

AstraZeneca plc demonstrates resilient growth through its diversified portfolio and robust R&D pipeline, with oncology leading the charge amid favorable industry tailwinds. Recent full-year results underscore operational strength, while ongoing pipeline advancements signal future potential. US investors benefit from its Nasdaq presence and US-centric revenue streams, though biopharma remains subject to regulatory and competitive dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.